Jeff Yorio, MD

Jeff Yorio, MD, discusses adverse effects associated with targeted agents and combinations in BRAF-mutated melanoma.

Jeff Yorio, MD, discusses treatment combinations in BRAF-mutated melanoma.

Jeff Yorio, MD, discusses treatment options for patients with rare mutations in metastatic lung cancer.

Jeff Yorio, MD, discusses the search for biomarkers and using next-generation sequencing in metastatic lung cancer.

Jeff Yorio, MD, discusses a small phase II study that is looking at using ado-trastuzumab emtansine to treat patients with HER2-mutant metastatic lung cancer.